Consequently, ATZ was recently approved by the Food and Drug Administration (FDA) for use as adjuvant treatment following resection and platinum‐based chemotherapy for adult patients with stage II to IIIA NSCLC whose tumors have PD‐L1 expression on ≥1% of tumor cells.12 Here, CD274 is linked to non-small cell lung carcinoma.